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SUMMARY
CCAAT enhancer-binding protein beta (C/EBPb) is a pioneer transcription factor that specifies cell
differentiation. C/EBPb is intrinsically unstructured, a molecular feature common to many proteins
involved in signal processing and epigenetics. The structure of C/EBPb differs depending on alterna-
tive translation initiation and multiple post-translational modifications (PTM). Mutation of distinct
PTM sites in C/EBPb alters protein interactions and cell differentiation, suggesting that a C/EBPb
PTM indexing code determines epigenetic outcomes. Herein, we systematically explored the interac-
tome of C/EBPb using an array technique based on spot-synthesized C/EBPb-derived linear tiling
peptides with and without PTM, combined with mass spectrometric proteomic analysis of protein
interactions. We identified interaction footprints of 1,300 proteins in nuclear extracts, many with
chromatin modifying, chromatin remodeling, and RNA processing functions. The results suggest
that C/EBPb acts as a multi-tasking molecular switchboard, integrating signal-dependent modifica-
tions and structural plasticity to orchestrate interactions with numerous protein complexes directing
cell fate and function.
INTRODUCTION
CCAAT enhancer-binding proteins (C/EBPa, b, d, 3) are basic leucine zipper (bZip) transcription factors
that regulate chromatin structure and gene expression by dimerization and binding to cis-regulatory, palin-
dromic 50ATTGC$GCAAT30, or quasi-palindromic DNA sites in gene enhancers and promoters. Prototypic
C/EBPb is widely expressed, highly regulated at the post-transcriptional level, and integrated in many
signaling events communicating extracellular cues to epigenetic changes, examples of which include
adipogenesis, hematopoiesis, innate immunity, female fertility, skin function, apoptosis, and cellular
senescence (Nerlov, 2008; Rodier and Campisi, 2011; Tsukada et al., 2011).
In early hematopoiesis and adipogenesis, C/EBPb acts as a pioneering factor that orchestrates complex
steps in cell fate commitment (Kajimura et al., 2009; Lichtinger et al., 2012; Muller et al., 1995; Ness et al.,
1993; Siersbaek et al., 2011). C/EBPb communicates with numerous other transcription factors, co-factors,
histone modifiers, and chromatin remodeling complexes to alter the susceptibility of chromatin to the
gene regulatory machinery. C/EBPb induces lymphoid-myeloid trans-differentiation and accelerates
acquisition of the induced pluripotent state by the Yamanaka set of reprogramming transcription factors
(Di Stefano et al., 2016; Kowenz-Leutz and Leutz, 1999; Stoilova et al., 2013; Xie et al., 2004). The chro-
matin and gene regulatory functionality of C/EBPb is linked to distinct regions and post-translational
modifications (PTMs) that suspend auto-inhibition, direct the activity of C/EBPb, and regulate recruit-
ment of chromatin remodelers and writers of histone modifications (Kowenz-Leutz and Leutz, 1999;
Kowenz-Leutz et al., 1994, 2010; Lee et al., 2010b; Mo et al., 2004; Pless et al., 2008; Siersbaek et al.,
2011).
C/EBPb functions are controlled by extracellular signaling cascades involving receptor tyrosine kinases,
cytokine receptors, Ras GTPases, mitogen-activated protein kinases, and cyclic AMP and SMAD signaling,
and by more complex conditions such as metabolic adaptation, inflammation, senescence, or stress
responses (Nerlov, 2008; Rodier and Campisi, 2011; Tsukada et al., 2011). The complexity and diversity
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participate in a multitude of regulatory events. Previous research suggested that the combinatorial
outcome of post-transcriptional modifications and PTMs in conjunction with intrinsic structural plasticity
enables the C/EBPb protein to adopt a plethora of context- and signal-dependent states that facilitate a
variety of interactions (Leutz et al., 2011; Nerlov, 2008; Tsukada et al., 2011).
Post-transcriptional regulation of C/EBPb generates three isoforms (LAP*, LAP, and LIP) by alternative
translation initiation of the single-exon C/EBPb transcript. As consecutive C/EBPb start sites are posi-
tioned in the same reading frame, the isoforms vary in their gene regulatory N-terminal extensions
but retain the same C-terminal dimerization and DNA-binding bZip domain (Wethmar et al., 2010).
The diversity of C/EBPb isoforms is further increased by numerous PTMs of amino acid side chains; in
addition to phosphorylation of serine, threonine, and tyrosine residues, lysine acetylation and methyl-
ation also occurs, as does methylation of arginine. Enzymes responsible for PTM of C/EBPb include
CARM1/PRMT4, G9A/EHMT2, and CREBBP/KAT3A, all of which also serve as epigenetic histone
code writers. The decoration of C/EBPb by PTM alters its capacity to engage in protein-protein interac-
tions (PPI) and to direct cell fate, suggesting that the signal-dependent C/EBPb modification index
reflects integration of various upstream signaling events to adjust its interactome and to determine its
gene regulatory and epigenetic capacity (Leutz et al., 2011). The combination of translational modifica-
tions and PTMs may thus encrypt the dynamic interactome, with C/EBPb being the keystone for a wide
range of functional outcomes (Lee et al., 2010b; Sebastian et al., 2005; Sterneck et al., 1997; Stoilova
et al., 2013).
The C-terminal third of C/EBPa, b, d, 3contains highly conserved DNA-binding and bZip domains that may
dimerize within an extended trans-regulatory bZip network including C/EBP, AP-1, and ATF transcription
factors. The N-terminal two-thirds region of the C/EBP primary structure is predicted as an intrinsically
disordered region (IDR) (Miller, 2006). Phylogenetic analysis, nevertheless, suggests that the C/EBP N ter-
minus also contains several highly conserved short peptide regions (CRs) that are enriched in amino acids
with hydrophobic and bulky side chains. These CRs are discontinuous and separated by less conserved and
family-specific regions of low complexity characterized by a predominance of small and polar amino acids
(Leutz et al., 2011; Tsukada et al., 2011). Experimental studies involving a large number of deletions and
CR/IDR shuffling mutants suggested a highly modular, context-dependent functionality of N-terminal
C/EBPb CRs (Kowenz-Leutz et al., 1994; Lee et al., 2010b; Leutz et al., 2011; Williams et al., 1995). Screening
for interaction partners using N-terminally derived C/EBPb peptides further supports the notion that many
C/EBPb interactions may occur in a modular and dynamic fashion that relies on molecular recognition
features (MoRFs) and short linear peptide motifs (SLiMs) in combination with adjacent PTMs (Dunker
et al., 1998; Leutz et al., 2011; Tompa et al., 2014; van der Lee et al., 2014; Wright and Dyson, 1999).
Based on previous observations of the modular structure and biological functionality of C/EBPb peptide
regions, we developed a novel technique to systematically explore the C/EBPb interactome. Briefly,
C/EBPb was deconstructed into small linear peptides of 14 amino acids immobilized on a solid-phase
matrix. The starting point for each peptide was shifted by four amino acids, creating a tiled peptide array
covering the entire amino acid sequence of C/EBPb. PTM-containing peptides were included according to
recorded modifications and their position in the primary C/EBPb structure. The matrix was incubated with
nuclear extracts, and protein enrichment on individual peptide spots was identified and quantified by mass
spectrometry. The assay, termed protein interaction screen on peptide matrices (PRISMA), revealed hun-
dreds of C/EBPb- and PTM-specific protein interactions that left footprints on C/EBPb-derived peptides.
Based on comparison with other affinity enrichment approaches, 45 protein complexes were predicted
and several novel interactions with proteins and complexes were experimentally confirmed.
RESULTS
The C/EBPb Peptide Matrix
The occurrence of novel PTMs on endogenous C/EBPb was investigated by mass spectrometry of C/EBPb
immunoprecipitates derived from the human anaplastic lymphoma cell line SU-DHL1 that critically
depends for growth and survival on C/EBPb (Anastasov et al., 2010; Jundt et al., 2005). Over 90 PTMs
were identified, which, combined with published data, suggested that more than 130 PTMs may occur
on this protein, as summarized in Figure 1A (Table S1). To systematically explore the C/EBPb interactome
and its PTM-specific regulation, we developed the PRISMA technology, which is based on a solid matrix
consisting of immobilized peptides spanning the entire primary structure of rat C/EBPb (297 amino acids),
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as schematically depicted in Figure 1B and detailed in Table S2. To cover all linear binding regions of the
entire CEBPb protein sequence, tiling peptides 14 amino acids long with an offset of mostly four amino
acids were spot synthesized on a cellulose acetate matrix using Fmoc synthesis. As PTMs were previously
shown to affect CEBPb protein interactions and functionality, PTM peptides with S/T/Y-phosphorylation;
K-acetylation; K-, R-methylation; and R-citrullination were included in the screen matrix. In total, the solid
matrix contained 203 immobilized peptides, covering known and potential post-translational side chain
modifications.
The C/EBPb PRISMA Screen
To examine the linear CEBPb interactome, two replicates of the peptidematrix were incubated with nuclear
extracts of HeLa cells. HeLa cells express CEBPb, and commercially available nuclear extracts have been
used successfully by many research groups for the purification of biologically active proteins and protein
complexes involved in gene regulation (Figure 1B). Individual peptide spots were excised and bound
proteins proteolytically digested and analyzed by high-resolution mass spectrometry. In total, 406 analyt-
ical mass spectrometric 1-h runs were performed (approximately 17 days of measurement), and spectra
were interpreted automatically using the MaxQuant software package.
Enrichment efficiency by PRISMA was examined by comparing the PRISMA intensity distribution with the
total proteome of the nuclear extract. Approximately 5,100 proteins were identified and quantified in
the nuclear cell extract using the intensity-based absolute quantification method (Schwanhausser
et al., 2011). The copy number of proteins in the nuclear cell extract and the number of proteins
bound in the PRISMA screen spans six orders of magnitude, suggesting that the identified binders
are not biased toward highly abundant proteins (Smits et al., 2013; Figure S1). Furthermore, the distribu-
tion of peptide or protein interactions was not attributed to physicochemical parameters of the
peptides, as evidenced by comparison of the accumulated interaction intensities with peptide hydropho-
bicity (gravy index) and isoelectric points, which were determined for all non-modified PRISMA peptides.
These results suggest that the PRISMA peptides on the matrix retained their specific protein-binding
properties.
Data Processing of C/EBPb Peptide-Binding Proteins
An initial inspection of the two replicate datasets revealed signal intensity variation of the interacting pro-
teins. The two datasets were therefore integrated to increase robustness, as outlined in Figure 1C and as
explained in the Methods. The main source of variation arose from proteins that were identified only once
on different peptide spots. This led to single (low confidence) and double (high confidence) identification
categories for each peptide. The signal intensity for each protein was then normalized between 0 and 1
across all 203 matrix peptides. Individual peptides displayed large differences in binding partner profiles,
further indicating the specificity of the interactions, because random binding would be expected to result
in a more equal distribution of interacting proteins. Further analysis of the data showed that 25% of the
identified proteins bound to multiple C/EBPb peptides across the array with low but varying intensity.
Although these proteins may promiscuously bind to many distant peptides, some sections of the array
showed much higher signals. To minimize noise from background binding, signal intensities for each
Figure 1. Outline of PRISMA Screen and Comparison of Data
(A) Schematic representation of C/EBPb and the distribution of known post-translational modifications. Conserved
regions (CRs) are depicted in color, whereas intrinsic disordered regions are shown in gray.
(B) Schematic description of the workflow of protein binding and data acquisition.
(C) Workflow of data and proteomic analysis.
(D) Overlap between the two replicates (SET1, SET2) of the PRISMA screen.
(E) Number of proteins in the two PRISMA datasets that show consecutive peptide binding (core interactions, dark
amber).
(F) Overlap of three affinity-purification-based datasets of C/EBPb interactors as described in the literature and combined
with data obtained from a proteomic interaction screen in SU-DHL1 cells. Overlaps were determined using
immunoprecitation (IP) SU-DHL1 as reference dataset and thus the numbers add up to the size of this set only (see
Methods).
(G) Overlap of the PRISMA-derived C/EBPb interactor datasets from (E) (union of SET1 and SET2, light amber) with core
interactions (dark amber) from the union of the three datasets from (F) (blue). Overlaps are given using the PRISMA-
derived data as reference datasets. The overlap count using the union of the datasets from (F) as a reference dataset is
denoted in brackets.
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protein were filtered for binding above 90% of the protein’s signal distribution (outlier filtering), removing
all signals below this threshold. Another filtering criterion for discriminating the most robust interactors
was based on the consecutive binding behavior of tiling peptides of the C/EBPb primary structure.
The rational here is that by shifting the sequence of tiling peptides by four amino acids, some of the
SLiMs and fractions thereof are included in more than one peptide. This may generate maximal binding
signals for peptides containing optimal SLiM and adjacent supporting amino acids, and attenuated
signals from neighboring peptides in which the particular SLiM is shifted or only partially included.
We used this predicted binding behavior to stringently filter the dataset further to remove all proteins
that failed the consecutive binding criterion (Figures 1D and 1E; see also Methods). In total, 2,363 interact-
ing proteins were identified (Table S3), of which 1,384 proteins were detected in both replicates and 1,302
proteins fulfilled the consecutive binding criterion and were defined as C/EBPb core interactions (bCI;
Figure 1E).
Validation of the PRISMA-Derived Dataset
To assess the biological significance of data derived by PRISMA, we compared PRISMAdata (SET1, SET2, bCI)
to previously identified C/EBPb interactome data, as shown in Figure 1F (Siersbaek et al., 2011; Steinberg
et al., 2012). In addition, we performed pull-down experiments using C/EBPb antibodies and SU-DHL1 cells
that express a high amount of CEBPb and analyzed the CEBPb interactome by mass spectrometry (Table S4).
In total, 1,369 proteins were significantly enriched in SU-DHL1 C/EBPb samples compared with control sam-
ples using a false discovery rate (FDR) cutoff of 5%. The list of SU-DHL1 C/EBPb interactors was included to
extend the existing CEBPb interaction datasets. The PRISMA core interaction data covered between 38% and
59% of the affinity-purification-based datasets (see Supplemental Information). Affinity purification-based
datasets were then combined, and the overlap with PRISMAdata was determined on the basis of their UniProt
identifier entries, as shown in Figure 1G (seeMethods). In total, 47% of data in all three sets were also found in
the PRISMA core interactions, and 64%of PRISMA core interactions were also found in at least one of the other
datasets. To estimate the FDR of the C/EBPb interactor data detected by PRISMA, we employed the method
proposed previously (D’Haeseleer and Church, 2004), which relies on comparing the intersections of protein
interaction datasets to approximate the number of false-positive PPIs. We obtained FDRs of 11.2% and 13.9%
for proteins detected in PRISMA replicates 1 and 2, respectively (SET1 and SET2 in Figures 1D and 1E; see
Supplemental Information for details). FDRs were reduced to values below 4% when applying the filtering
step leading to PRISMA core interactions. These results suggest that PRISMA data depict strong overlap
and extensive coverage of the interactome related to native C/EBPb. We conclude that the PRISMA method
successfully extends the interactome data and serves as a resource for locating interaction footprints on
C/EBPs.
High-Resolution C/EBPb Interactome Footprints
The global protein interaction profile obtained from the C/EBPb peptide matrix is depicted as a non-
hierarchically clustered heatmap in Figure 2A. The numerical distribution of proteins identified by
individual peptides is shown in the upper part of Figure 2A. Peptides representing the DNA-binding
region (DB) and the C-terminal part of the leucine zipper (LZ) exhibit the highest number of protein
interactions, yet locally enriched binding hotspots were also found with peptides from the N-terminal
part of C/EBPb.
Clusters of protein-peptide interactions tended to co-localize with regions predicted to undergo disorder-
to-order transition during interaction with binding partners and coincide with the profile of conserved
C/EBPb regions (CR17), interaction and MoRF predictions (Disfani et al., 2012; Meszaros et al., 2009),
as shown in Figure 2B. Predicted IDRs in the transactivating domain (CR14), IDR2 (between CR2
and CR3), and regulatory domain between CR7 and the basic or acidic region (IDR7) also displayed
large numbers of interaction partners.
Figure 2. Distribution of Protein Interactions Discovered by PRISMA
(A) Heatmap of the normalized intensities of interaction partners. The bar graph (top) shows the distribution of accumulated protein interactions by
normalized binding intensities for each peptide. The tiled peptides of C/EBPb (below) are plotted on the horizontal axis, and proteins are shown on the
vertical axis following non-supervised hierarchical clustering.
(B) Prediction of C/EBPb interaction regions using ‘‘Anchor’’ (blue) and ‘‘MoRF’’ (magenta) bioinformatics tools and prediction of intrinsic disorder (gray) in
relation to the schematic representation of C/EBPb and the primary structure (bottom of A). Different conserved regions are colored as shown in Figure 1A.
(C) Heatmaps of selected complexes.
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Next, PRISMA-derived data were compared with previously mapped C/EBPb-interacting proteins. As
shown in Figure 2C, both co-activator acetyltransferases, CBP and P300 (KAT3A/KAT3B), generated
highly similar interaction footprints in the transactivation regions CR4 (strongest binding) and CR3 (additional
binding), with some residual binding in CR2. Both C/EBPb and C/EBPd have been shown to interact
with CBP/p300, and the main interaction region encompasses the CBP Taz2 domain as well as CR3
and CR4 in both C/EBPs. Removal of CR3 or CR4, or mutation of a critical tyrosine residue in CR3 or
the DLF motif in CR4 all abrogated interaction with Taz2 and subsequent transcriptional co-activation
(Kovacs et al., 2003; Schwartz et al., 2003). Previously published crystallographic data revealed that
CR3/CR4 regions in C/EBP 3may adopt an L-shaped a-helical structure that folds into the p300 Taz2
domain (Bhaumik et al., 2014), in agreement with the CBP/P300 protein footprints revealed by PRISMA
(Figure 2C).
The multi-subunit Mediator (MED) complex (Conaway and Conaway, 2013; Jeronimo and Robert, 2017)
has also been reported to interact with C/EBPb (Mo et al., 2004), and several MED components were
identified in a previously published C/EBPb interaction dataset (Siersbaek et al., 2014), as well as in the
SU-DHL1 interactome presented here. As shown in Figure 2C, PRISMA revealed 20 components of the
multi-subunit MED complex that predominantly interact with CR2-, CR3-, and CR4-derived peptides
from C/EBPb TAD.
CR1 of the LAP* C/EBPb isoform was reported to specify conjugation by SUMO3 (Eaton and Sealy, 2003)
and in accordance, PRISMA showed interaction between SUMO3 and CR1. CR1 also interacts with
the Brg1/SMARCA4 ATPase of the SWI/SNF/BAF complex. Moreover, the Brg1-CR1 interaction is sensitive
to methylation of arginine 3 (Kowenz-Leutz et al., 2010). Consistent with these results, PRISMA revealed
interaction of Brg1 with the unmodified CR1 peptide, but not with the methylated peptide. Moreover,
interactions with 10 additional protein components of BAF-SWI/SNF-type protein complexes were
detected with various peptides of the C/EBPb transactivation domain and the bZip domain, indicating
multiple interactions between C/EBPb and chromatin modifying complexes, as previously suggested
(Kowenz-Leutz and Leutz, 1999).
The Landscape of CEBPb Protein Interactions
PRISMA data (SET1 and SET2) were inspected for enrichment of Gene Ontology (GO) terms, protein fam-
ilies, and protein domains. As shown in Table 1, sorting of C/EBPb interaction hits based on the quantity of
terms resulted in exceedingly low Benjamini-Hochberg corrected FDRs (cutoff at a Benjamini-Hochberg
corrected p value of 0.01) (Finn et al., 2016, 2017; Gene Ontology, 2015). Strongly enriched terms included
‘‘nucleic acid binding’’ (745 hits), ‘‘gene expression’’ (611 hits), ‘‘protein binding’’ (534 hits), ‘‘regulation of
transcription’’ (301 hits), ‘‘cell cycle’’ (211 hits), ‘‘RNA splicing’’ (172 hits), and several terms involving tran-
scription, chromatin binding, and remodeling. Gene set enrichment analysis showed that approximately
25% of PRISMA-replicate-validated proteins (267) fell into categories that involve GO terms related to
RNA processing (FDR 5.63 3 10128). RNA-binding proteins that contain an RNP-1 RNA-binding domain
fall into three classes that preferentially interact with the C/EBPb bZip domain and the adjacent Fork
and BA motifs, whereas a third group interacts with the CR2 region. A similar binding pattern was found
for DEAD box helicases, a group of enzymes involved in ATP-driven conformational adjustment of ribonu-
cleoprotein assembly.
Protein domain enrichment using InterPro and PFAM databases revealed nucleotide-binding proteins (102
hits), RNA-binding proteins (80 hits), armadillo, WD40, histone fold, and DEAD box domain proteins as
major C/EBPb interaction partners. The number of domain hits obtained using standard algorithms to
search protein domain databases may be underrepresented, because manual curation of PRISMA data
increased the number of hits for WD40 domain proteins (IPR017986: WD40 repeat, region) from 32 to
40, and the number of DEAD box proteins (IPR011545: DNA/RNA helicase; DEAD/DEAH box type, N-ter-
minal) from 20 to 24.
The C/EBPb structure is predicted to fold back onto itself, permitting intramolecular signaling, or to stretch
out to allow contact with several interaction partners simultaneously (Kowenz-Leutz et al., 1994; Lee et al.,
2010a; Lynch et al., 2011). A strong indication of the involvement of multiple contacts with interaction part-
ners through adjacent or distant C/EBPb regions is shown in Figure S2A, which lists multivalent interactions,
including potential interactions with different proteins of the same complex.
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Enrichment Score Pathway/Domain Description Counts in PRISMA FDR
GO: Biological Processes
GO:0010467 Gene expression 611 4.19 3 10103
GO:0006355 Regulation of transcription, DNA-templated 301 1.27 3 107
GO:0006396 RNA processing 267 5.63 3 10128
GO:0007049 Cell cycle 211 3.06 3 1031
GO:0008380 RNA splicing 172 7.14 3 10106
GO:0051276 Chromosome organization 169 1.16 3 1034
GO:0006461 Protein complex assembly 128 4.17 3 1012
GO:0016568 Chromatin modification 89 2.50 3 1013
GO:0051169 Nuclear transport 86 9.46 3 1038
GO:0006281 DNA repair 84 9.48 3 1017
GO: Molecular Function
GO:0003676 Nucleic acid binding 745 3.8 3 10199
GO:0003723 RNA binding 607 0E+00
GO:0005515 Protein binding 534 1.92 3 1040
GO:0003677 DNA binding 269 6.43 3 1017
GO:0005524 ATP binding 216 2.82 3 1024
GO:0003682 Chromatin binding 94 4.43 3 1018
GO:0003712 Transcription cofactor activity 81 2.27 3 109
GO:0008134 Transcription factor binding 66 5.86 3 109
GO:0019900 Kinase binding 61 3.30 3 106
GO:0004693 Cyclin-dependent protein serine/threonine
kinase activity
17 6.20 3 1010
GO: Cellular Component
GO:0000785 Chromatin 103 6.04 3 1031
GO:0005681 Spliceosomal complex 85 5.10 3 1056
GO:0005643 Nuclear pore 32 9.77 3 1019
GO:0030880 RNA polymerase complex 30 2.98 3 1010
GO:0070603 SWI/SNF superfamily-type complex 28 9.63 3 1014
GO:0034708 Methyltransferase complex 24 4.86 3 109
GO:0016592 Mediator complex 20 3.98 3 1013
GO:0000178 Exosome (RNase complex) 12 4.26 3 109
GO:0016581 NuRD complex 11 1.50 3 109
GO:0016593 Cdc73/Paf1 complex 6 1.01 3 105
Table 1. C/EBPb Interactome Enriched Gene Ontology (GO) Terms
(Continued on next page)
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Discrete parts of the C/EBPb primary structure have previously been assigned to different biochemical or
cellular functions. Protein binding data from different C/EBPb regions were extracted andGO term analysis
performed for each of the regions to map structure-function relationships, as shown in Figure S2B. Some
functional attributions displayed partition over several regions of C/EBPb (regulation of gene expression,
RNA splicing), whereas others are more localized to distinct regions. For example, basic regions and DB
show strong enrichment for ‘‘regulation of mitotic cell cycle processes’’ or ‘‘nuclear export,’’ whereas
‘‘nuclear import’’ is associated with CR5, CR7, IR7, and LZ. The C-terminal region of C/EBPb is involved
in the majority of GO terms, whereas transcription factor co-activator functions are mainly associated
with N-terminal activation of CR2, CR3, CR4, and IR7.
C/EBPb-Interacting Protein Complexes
Next, PRISMA data were analyzed for potential enrichment of large protein complexes interacting with
CEBPb. In addition to anticipated C/EBPb-interacting complexes such as the basic RNA polymerase II
(RNAPII) transcription machinery or MED, previously unknown interrelations became apparent. These
included potential complexes involved in the RNA transcript processing machinery responsible for
transcript capping, splicing, termination, and polyadenylation. Interactions included 3’- end processing,
cleavage, and polyadenylating factor (CPSF1, 3, 7, 30, and 100), and several components of the Integrator
complex involved in small nuclear RNA (snRNA) expression and the RNA exosome (EXOSC2, 4, 6, 7, 8, 9,
Enrichment Score Pathway/Domain Description Counts in PRISMA FDR
Interpro Domains
IPR027417 P loop containing nucleoside triphosphate
hydrolase
102 9.71 3 1030
IPR000504 RNA recognition motif domain 80 8.77 3 1053
IPR005225 Small GTP-binding protein domain 41 2.11 3 1013
IPR016024 Armadillo-type fold 34 1.69 3 1011
IPR017986 WD40-repeat-containing domain 32 6.78 3 1010
IPR009072 Histone-fold 27 3.89 3 109
IPR001650 Helicase, C-terminal 23 1.94 3 1014
IPR011989 Armadillo-like helical 21 5.11 3 106
IPR011545 DEAD/DEAH box helicase domain 20 2.11 3 1013
IPR002041 Ran GTPase 20 5.34 3 1012
PFAM Domains
PF00076 RNA recognition motif. (also called RRM,
RBD, or RNP domain)
72 4.32 3 1049
PF00071 Ras family 31 8.17 3 109
PF00400 WD domain, G-beta repeat 29 1.38 3 1010
PF00271 Helicase-conserved C-terminal domain 23 2.27 3 1014
PF00125 Core histone H2A/H2B/H3/H4 23 1.89 3 109
PF00270 DEAD/DEAH box helicase 20 2.63 3 1013
PF00013 KH domain 10 1.36 3 106
PF00244 14-3-3 protein 6 2.32 3 104
PF01423 LSM domain 9 2.32 3 104
PF00538 Linker histone H1 and H5 family 5 4.50 3 104
Table 1. Continued
iScience 13, 351–370, March 29, 2019 359
360 iScience 13, 351–370, March 29, 2019
and 10). Furthermore, many components of the nuclear pore and associated adapter complexes were iden-
tified. In addition, components of the transcript export THO-TREX complex, including THO1, 2, 3, 5, 6, 7,
Aly, DDX39, and the THO-TREX-associated mRNA export factors Nxf1-Nxt1 were identified, along with a
large number of heterogeneous nuclear ribonucleoproteins that may couple transcript splicing, matura-
tion, and the formation of messenger ribonucleoprotein particles. Taken together, these data imply the
existence of a previously unknown connection between CEBPb and several steps involved in transcript
generation, processing, maturation, and transport (Muller-McNicoll and Neugebauer, 2013; Wickrama-
singhe and Laskey, 2015).
Proteins co-occurring in both the PRISMA and SU-DHL1 proteomic data were then systematically explored
to identify soluble protein complexes listed in the CORUM database (March 6, 2017) using the g:Profiler
bioinformatics toolkit (Reimand et al., 2016; Ruepp et al., 2010). A list of 1,432 human protein complexes
built from 2,678 proteins (single UniProt identifier; ID) was derived after removal of redundant and non-
human complex entries. Proteins listed in PRISMA replicates (SET1 + SET2) and protein interactions
derived from SU-DHL1 IP-mass spectrometry data were matched by UniProt and gene name ID using
Perseus version 1.5.2.4 (Tyanova et al., 2016). Redundant gene names and isoform entries were merged
into a single UniProt ID for each protein. Altogether, 816 proteins of the PRISMA-derived dataset and
490 proteins of the IP SU-DHL1 dataset were included in any of the 1,432 CORUM complexes. The 1,432
CORUM complexes were then ranked by a combination of two criteria: (1) the percentage of proteins in
complexes obtained by PRISMA and (2) deviation from randomness of the coverage of the complexes
obtained by PRISMA and SU-DHL1 (p values with CORUM background, see Supplemental Information
for details). Considering only complexes sharing at least one protein with the PRISMA dataset and which
have at least three overlaps with PRISMA and SU-DHL1 data resulted in a ranked list of 417 candidate
complexes (see Figure S3 and Table S5). Whenever possible, complexes were grouped into categories
indicating functional connections, such as DNA repair, nuclear pore, or centromere, in addition to
well-characterized multi-subunit complexes, such as MED, SWI/SNF, MLL, nucleosome remodeling deace-
tylase (NuRD), and others. As shown in Figure 3A, 45 multi-protein complexes and categories were
extracted, and normalized protein interaction values at any of the 203 C/EBPb peptides were summed
over all instances of the category in the list and depicted as a bar plot to visualize the distribution of inter-
action sites of different categories or complexes in relation to the C/EBPb primary structure. These 45
entities were composed of 30 complexes or categories representing the full upper quartile of the ranked
complex list (i.e., up to rank 104, Table S5, withminor exceptions, Figure S3), together with 15 lower-ranking
functional counterparts. Figure 3B shows prominent node-link diagrams of a selection of 14 multi-protein
complexes among the highest ranking categories that share many proteins identified by both PRISMA and
SU-DHL1 immunoprecipitation methods.
Validation of Region- and PTM-Specific C/EBPb Interactions
Next, conventional protein pull-down, immunoprecipitation, and immunoblotting analysis were used in
combination with CEBPb mutants to validate data from the PRISMA-derived interactome (Figure 4).
According to PRISMA, the nuclear factor kappa B subunit RelA, the signal transducer and activator of tran-
scription STAT3, and the nuclear pore complex protein NUP50/NPAP60L predominantly interacted with
peptides located in CR7. Bacterially expressed GST-C/EBPb constructs were probed with HEK293 extracts
to examine RelA and NUP50/NPAP60L interactions. As shown in Figures 4B and 4D (lower panels) affinity
capture with GST-CEBPb constructs or co-immunoprecipitation of STAT3 with the C/EBPbmutant protein
lacking CR7 and subsequent immunoblotting confirmed CR7 as the interaction site for all three proteins.
The histone acetyltransferase GCN5 of the SAGA complex and the DNAmethyltransferase-associated pro-
tein DMAP1 of the NuA4/TIP60 acetyltransferase complex are involved in a wide variety of developmental
and genome regulatory activities, including transcription, DNA repair, DNA methylation, and chromatin
remodeling (Mohan et al., 2006; Weake and Workman, 2012). DMAP1 and GCN5 engage in major binding
Figure 3. PRISMA-Based Prediction of Protein Complexes Interacting with C/EBPb
(A) Bar graphs of accumulated normalized intensities for 45 selected complexes. Based on CORUM database protein complex annotations, the
corresponding normalized intensities of proteins identified by PRISMA were extracted and plotted.
(B) Network representation of 14 potential complexes identified. Nodes are color coded according to their detection in PRISMA and SU-DHL1 IP
experiments (yellow, detected in IP and PRISMA; green, detected in IP; dark blue, detected in the PRISMA core set; light blue, detected in PRISMA SET1 and
SET2).




Figure 4. Validation of Site-Specific Interactions with C/EBPb
(A) Accumulated binding intensities of interaction partners (indicated on the left) from the PRISMA screen. Bar graphs
indicate interactions according to the peptide position in C/EBPb, as schematically shown underneath.
(B) Top, left: Color-coded scheme of the C/EBPb protein with dashed lines to aid comparison of constructs shown in
(B–D). Top, right: Immunoblots (right) showing interaction of RelA and Nup50/NPAP60L of HEK293T cell lysates with
bacterially expressed GST-C/EBPb constructs. Integrity of GST-C/EBPb constructs was examined by immunoblotting (as
indicated). GST constructs were probed with anti-GST and a polyclonal C/EBPb antibody that preferentially, but not
exclusively, recognizes CR7 as a major epitope. Themost intense signals of RelA andNup50/NPAP60L are associated with
the presence of the CR7 region of C/EBPb. A, antibody; IP, immunoprecipitation; IB, immunoblotting.
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to CR3 and CR4, respectively, and minor binding elsewhere in C/EBPb. Various C-terminally FLAG-tagged
C/EBPb mutant constructs lacking CR1, CR2 (5D43), the entire TAD (5D141), CR4 (LAP*D4), CR7 (LAP*D7),
or both CR4 and CR7 (LAP*D4,7) were expressed in HEK293 cells to examine selective and multi-site
interaction with resident DMAP1/GCN5 or their respective complexes. As shown in Figures 4C and 4D,
pull-down and immunoblotting revealed that removal of the DMAP1 minor binding site in CR2 partially
abrogated the interaction and removal of binding to CR3 completely abrogated the interaction. Similarly,
removal of the binding site for GCN5 located in CR4 strongly affected GCN5 association and deletion of
the binding site in CR7 entirely abolished binding to C/EBPb.
The Impact of PTMs on C/EBPb-Mediated Interactions
Detection of PTM-dependent protein interactions in linear C/EBPb peptides was a major objective for the
development of the PRISMA screening method. Protein binding to each PRISMA peptide and its PTM-
modified versions were therefore examined. The binding signal for each protein was normalized against
the signal from the corresponding unmodified peptide to compare enhanced or reduced binding. Interact-
ing proteins were then clustered, as shown in Figure S4. Depending on PTM, as exemplified in Figure 5A,
interactions fell into the following four categories: (1) generally repressed binding, (2) PTM-independent
binding, (3) PTM-specific binding, and (4) generally enhanced binding. Most of the identified binding part-
ners were indifferent to the type of PTM and were classified as binding proteins that may recognize parts of
the peptide sequences. Generally enhanced binding may in part relate to the fact that many PTMs increase
hydrophobicity and may thus enhance interactions non-specifically. The most interesting binding partners
are expected to be found in the last two categories and represent proteins that are disturbed by any PTM in
the peptide or represent interaction partners that were attracted or repelled by a particular PTM. Examples
of the latter are the NuA4/TIP60 complex components DMAP1 and YEATS4, both binding to CR3, or RelA
and the transducin-like enhancer protein TLE3 binding to CR7, which depends on the methylation status of
arginine residues that were subsequently examined.
The transactivation region CR3 (residues 53–68: AIGEHERAIDFSPYLE) contains an arginine residue that is
conserved in C/EBPb, but not in C/EBPa,d, 3, and was previously found to be methylated (Leutz et al., 2011).
The PRISMA data suggested that DMAP1 and YEATS4 binding to CR3 depended on methylation of R59.
Another interaction hotspot was mapped to the start site of the highly conserved, alternatively initiated LIP
C/EBPb isoform that also represents part of the regulatory regionCR7 (residues 158–170: FPFALRAYLGYQAT).
The respective arginine residues in both chicken (R60, R193) and rat (R58, R162) were previously found to be
methylated. Mutation of the equivalent amino acid residue to alanine or leucine in chicken C/EBPb strongly
altered transcriptional activity, suggesting that the methylation status of the conserved arginine in CR7 may
be critical (Leutz et al., 2011). Wild-type (WT) C/EBPb, methylation-defective R60A and R193A, and methyl-
ation-mimicking R60L and R193L constructs were subjected to co-immunoprecipitation to compare
alterations in binding, as shown in Figure 5B. As suggested by PRISMA, interaction of all four proteins with
C/EBPb was sensitive to the amino acid side chain configuration at the respective arginine positions, demon-
strating both amino acid and PTM specificities, in addition to evolutionary conservation of chicken and rat
C/EBPb interactions. Binding of YEATS4 or DMAP1 to C/EBPb was enhanced or tolerated by the R60L
exchange, but not the R60A exchange, respectively, confirming the side chain specificity and preference for
increased side chain hydrophobicity. RelA binding to the R193A mutant was slightly enhanced when
compared with WT or reduced by the R193L mutant, respectively, confirming avoidance of the methylated,
more hydrophobic PRISMA peptide. By contrast, the TLE3 co-repressor (Agarwal et al., 2015) favored binding
to the R193L mutant, suggesting that the increase in hydrophobicity by methylation of the arginine side chain,
but not the positive charge, was important for interaction with TLE3. Pull down of TLE3 by immunoprecipita-
tion confirmed preferential binding of C/EBPbR193L, as shown in Figure 5C. Next, we performed methylation
assays with the protein arginine methyltransferase PRMT4/CARM1 and C/EBPb peptides, as shown in
Figure 5D. C/EBPbR193 was identified as a methylation target in CR7, in addition to the previously described
R3 in CR1 (Kowenz-Leutz et al., 2010). Co-immunoprecipitation of TLE3 together with WT C/EBPb was
dependent on co-expression of PRMT4/CARM1 (Figure 5E). Importantly, and irrespective of co-expressed
Figure 4. Continued
(C) Co-immunoprecipitation of FLAG-tagged LAP* C/EBPb or three N-terminal C/EBPb deletion mutants, followed by
immunoblot detection of co-precipitated DMAP1 from HEKT cells.
(D) Immunoprecipitation of HEKT cell expressing LAP* and three different internal deletion mutants of C/EBPb followed
by immunoblot detection of GCN5 and Stat3.
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PRMT4/CARM1, themethylation-defective C/EBPbR193Amutant failed to bind TLE3, confirming C/EBPbCR7
arginine side chain methylation as a prerequisite for binding to TLE3.
Both C/EBPb and TLE3 had been described as important regulators in adipogenesis (Villanueva et al.,
2013). As shown in Figure 5F, ectopic expression of C/EBPb in 3-isobutyl-1-methylxanthine (3T3L1) cells
induced partial adipogenic differentiation in the absence of the in vitro differentiation cocktail (IBMX,
insulin, dexamethasone). Fat cell differentiation was evident by up-regulation of the adipogenic genes
ADIPOQ, CFD, and FABP4 (Figure 5F, bar graph panel) and enhanced oil red O staining (below) in local
adipogenic nests. Adipogenic gene expression of ADIPOQ and FABP4 was enhanced by the C/EBPbR193L
mutant, and TLE3 cooperated with C/EBPb WT and more strongly with C/EBPbR193L, but not with the
C/EBPbR193A mutant, to activate ADIPOQ, CFD, and FABP4. We conclude that PRISMA may uncover
functional C/EBPb PTM-regulated protein-protein interactions to adjust the biology of C/EBPb.
Novel Connections between C/EBPb, Transcription Elongation, MLL, and NuRD
Of particular interest was the observation that many proteins forming part of the machinery involved in
RNAPII pausing and elongation were included in the PRISMA data. Components of the Trithorax MLL/
Set1/COMPAS histone H3 lysine 4 (H3K4) methyltransferase complexes (Shilatifard, 2012) were also repre-
sented in the dataset, raising the possibility of a connection between C/EBPb, enhancer/promoter binding,
and regulation of RNAPII processivity. Many components implicated in both processes were found,
including the MLL complex components CHD3 and 4 (Mi-2), ASH2, Dpy30, PTIP, and HCF-1; the general
transcriptional elongation factor B (TFIIS) and associated elongin A/B/C factors (Aso et al., 1995); the
P-TEFb components cyclinK/T1, cdk9, and additional regulatory components including LARP7, HEXIM1,
SPT5 (DSIF), and the chromatin adaptor bromodomain factor Brd4 and components of the super elonga-
tion complex (SEC), including AF9, PCAF1, and AF4 (AFF1) (Luo et al., 2012). AFF1 is a central SEC scaffold
component, and AF9 and ENL are highly similar YEATS domain family members that compete for binding
to AFF1. The N-terminal YEATS domain of AF9 and ENL both bind to the PAF complex to connect SEC to
RNAPII on chromatin templates. The CDK9/CYCT1 P-TEFb complex is required for rapid transcriptional
induction, phosphorylation of the C-terminal domain of RNAPII, and engagement of BRD4, which also
interacts with H3K9ac. P-TEFb is also associated with a 7SK snRNA subcomplex that contains the regulatory
components LARP7, HEXIM1, and SPT5 (DSIF) and connects to PAFc in the dynamic transcription elonga-
tion machinery (He et al., 2011; Luo et al., 2012; Peterlin and Price, 2006). In addition, the histone chaperone
FACT complex facilitates passage of the transcription apparatus through chromatin and is thought to
restore the chromatin structure and the epigenetic state during transcription, replication, and repair (Ham-
mond et al., 2017; Hondele and Ladurner, 2013; Orphanides et al., 1998).
Immunoprecipitation and immunoblotting were performed to validate several of these novel connections.
As shown in Figure 6, multiple MLL, FACT, and SEC components were all co-immunoprecipitated with
C/EBPb, confirming the predictive capacity of PRISMA. It is also important to note that AFF1, AF9, and
Figure 5. PTM-Specific C/EBPb Interactions
(A) PTM-dependent protein binding to FPFALRAYLGYQAT peptides of C/EBPb CR7. Normalized binding intensity relative to the unmodified peptide. Four
binding categories are considered: proteins with reduced binding by any PTM (repressed, blue, far left), proteins not responding tomodifications on C/EBPb
(independent, yellow, middle), proteins with PTM-specific binding (regulated, yellow-red, small), and enhanced binding by any PTM (enhanced, red, far
right).
(B) Immunoprecipitation (IP) from transfected HEK293T cell lysates: FLAG-tagged C/EBPb wild-type (WT) or mutants, as indicated, abrogating (C/EBPb
R60A; R193A) or mimicking (C/EBPb R60L, R193L) methylation. Co-immunoprecipitation (coIP) of endogenous YEATS4 and DMAP1 detected by
immunoblotting. YEATS4 and DMAP1 bind to C/EBPbR60L and failed to bind to the R60A C/EBPb mutant. RelA favors WT or C/EBPbR193A binding over
R193L. TLE3 preferentially binds to C/EBPbR193L. Underneath: Expression controls of endogenous YEATS4, DMAP1, RelA, and TLE3.
(C) coIP of WT and mutant C/EBPb, as indicated, with hemagglutinin (HA)-tagged TLE3. C/EBPbR193L, but not WT or R193A, co-IPs with TLE3.
(D) In vitromethylation of C/EBPb peptides by CARM1. Scheme of C/EBPb with approximate positions of peptides and R-residues indicated by red bars and
dots; R residue sequence positions underneath. Bar graphs show peptide-specific incorporation of methyl group from donor S-adenosyl-L-[methyl-3H]
methionine.
(E) coIP of C/EBPb with TLE3 depends on CARM1. Co-expression of WT C/EBPb (R) or mutants (R193A, R193L), TLE3, and CARM1 are indicated on the top.
WT C/EBPb, but not R193A, co-immunoprecipitates with TLE3 in the presence of CARM1, whereas the C/EBPbR193L mutation supersedes CARM1
requirement.
(F) RT-PCR of ADIPOQ, CFD, and FABP4 expression (arbitrary units: target gene to internal 36B4 expression control) induced by C/EBPbWT, R193A, R193L,
or vector control in the absence or presence of TLE3 in NIH 3T3 L1 cells without adipogenic differentiation cocktail (upper panel; n = 3, ANOVA; *p% 0.05,
**p% 0.01, ***p% 0.001; ns: not significant). Oil red O staining of stably transfected NIH 3T3 L1 cells with C/EBPb constructs, vector control and TLE3, as
indicated, 3 weeks post-confluency (middle panel, representative images) and protein expression controls (lower panel).
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ENL are among the most frequent oncogenic fusion partners with the MLL gene product that transforms
early hematopoietic progenitors and causes childhood leukemia by short-circuiting enhancer and pro-
moter activation and transcriptional elongation checkpoint controls (Krivtsov and Armstrong, 2007; Shila-
tifard, 2012; Slany, 2009; Smith et al., 2011).
The Mi2/NuRD corepressor complex is widely expressed and maintains chromatin in a closed state by ATP-
dependent chromatin remodeling and histone tail deacetylation. Some of the NuRD components (CHD3/
4(Mi2), HDAC1, RBBP4/7, MTA1,2, GATAD2A/p66a, MBD2, MBD3) identified by PRISMA, SU-DHL1 IP, and
other approaches (Steinberg et al., 2012; Siersbaek et al., 2014) are shared with the SIN3A andCoREST repres-
sion complexes (Gregoretti et al., 2004), and all were implicated by CORUM analysis (Figures 3 and S3, Table
S5). Two major NuRD complexes contain the unique methyl-CpG-binding proteins MBD3 or MBD2, of which
the latter may also associate with the WDR77(MEP50)/PRMT5 sub-module (Le Guezennec et al., 2006; Zhang
and Yinghua, 2011). Immunoprecipitation of either MBD2 or MBD3 revealed association of C/EBPb, Mi2, and
A C
B D
Figure 6. C/EBPb-Interacting Multi-protein Complexes in HEK293T Cells
(A) Co-immunoprecipitation of FLAG-tagged C/EBPb and the MLL/Ash2/Wdr5 complex.
(B) Left panel: FLAG-tagged C/EBPb was co-expressed with GFP-tagged Spt16 and SSRP1. Right panel: Immunoprecipitation of FLAG-tagged C/EBPb co-
precipitates both endogenous FACT complex subunits.
(C) Interaction with the super elongation complex. Immunoprecipitation of human C/EBPb (C/EBPb) pulls down the entire super elongation complex.
(D) Interaction with the NuRD complex. The integral subunits of the NuRD complex MBD2 (HA-tagged) and MBD3 (GFDP-tagged) were pulled down by
immunoprecipitation. Detection by western blot shows that C/EBPb interacts with both subunits. IB, immunoblotting; IP, immunoprecipitation.
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MTA with both MBD components, whereas only MBD2 co-precipitated with the WDR77(MEP50)/PRMT5
sub-module, suggesting that C/EBPb may associate with both types of NuRD complexes.
DISCUSSION
In conclusion, the PRISMA technique reveals a comprehensive and PTM-dependent interactome of the
disordered C/EBPb transcription factor hub and permits the detection of footprints of protein interactions
and protein complexes. The results presented in this article suggest that C/EBPb is involved at the nexus
between enhancer and promoter regulation, in many aspects of pre- and post-transcriptional control,
including initiation and pausing control, splicing and exosomal RNA degradation, polyadenylation, and
RNA maturation, and in nuclear export. Previously, we described an array peptide screening system
(APS) for PTM-dependent protein interactions that relied on fluorophore-based detection of peptide inter-
actions with bacterially expressed human proteins immobilized on macroarrays. Although it is difficult to
compare APS with PRISMA because of major differences in peptide choice, peptide length, biochemical
conditions, local concentration of interaction partners, signal-to-noise ratio, or complexity of the protein
expression library and requirement of a renaturation step, 35 common APS/PRISMA interaction partners,
including Brg1/SMARCA4, were found with an N-terminal APS peptide and a comparable section covered
in PRISMA that contained CR1 (Pless et al., 2011).
The high local concentration of peptides in matrix spots may limit free diffusion and overcome the disso-
ciation problem of low-affinity interactions (Ruthenburg et al., 2007). These features permit the detection of
weak interactions and interactions with rare protein partners. The interaction screen developed herein is
augmented by inclusion of amino acids with modified side chains to enable detection of PTM-dependent
interactions on a global scale. Together, the interaction footprints and PTM-dependent data may help in
the rational design of mutants to further explore the functional C/EBPb interactome and aid in the devel-
opment of pharmacological inhibitors of protein interactions. The PRISMA workflow is applicable to other
regulatory proteins and particularly to transcriptional regulators with a high degree of intrinsic disorder,
such as Myc- or various Hox proteins. PRISMA may help to discern highly complex and dynamic transcrip-
tion factor functions that arise through IDR- and PTM-regulated interactions.
PRISMA was developed for analysis of the interactome of proteins with a high degree of intrinsic disorder.
Such proteins lack a defined 3D structure, and protein interactions and complex formation are based on
SLiMs, PTMs, and intrinsic flexibility. IDRs in conjunction with PTMs may facilitate structural transitions in
partner protein exchanges (Wright and Dyson, 2015). Comprehension of the dynamics and context-depen-
dent interactions between structurally flexible SLiMs and various partner proteins is an emerging hallmark
of signal transmission and key to understand the regulation of chromatin structure and gene expression
(Minde et al., 2017; Tompa et al., 2014; van der Lee et al., 2014; Wright and Dyson, 2015). SLiM interactions
often occur with high specificity but low affinity to enable multiple contacts of a dynamic nature, such as
occurring during phase separation. Deciphering the functionality of SLiM/MoRF-type protein regions
and PTMs in homeostasis and disease can be challenging when using full-length proteins due to functional
redundancy and compensatory effects. A variant of PRISMA has meanwhile been employed to detect
dysregulated interactions with disease-causing mutations occurring in IDRs (Meyer et al., 2018). PRISMA
data presented here thus provide a repository of high-molecular-resolution C/EBPb interactions and serve
as a basis to explore gene regulatory and PTM-modulated C/EBPb functions.
Limitations of the Study
Protein interactions can be mediated by binding domains or by smaller interaction motifs. One key aspect
of the study is the identification of the interactome of IDRs and SLiMs and binding regulation by PTMs. As
the PRISMA technique is based on the use of peptides, the detection of interactions is limited to those that
are based on structurally variable SLiMs, as binding directly depends on the amino acid sequence proper-
ties. The high local concentrations of the peptides on the membrane permit the detection of low-affinity
interactors and leave components of their corresponding protein complexes intact under mild washing
conditions. For interactions that are based on recognition of three-dimensional structures, however, the
method will probably not be applicable.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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PRISMA: Protein Interaction Screen on Peptide Matrix
Reveals Interaction Footprints and Modifications-
Dependent Interactome of Intrinsically Disordered C/EBPb
Gunnar Dittmar, Daniel Perez Hernandez, Elisabeth Kowenz-Leutz, Marieluise
Kirchner, Günther Kahlert, Radoslaw Wesolowski, Katharina Baum, Maria
Knoblich, Maria Hofstätter, Arnaud Muller, Jana Wolf, Ulf Reimer, and Achim Leutz

Supplemental Figure 1: Comparison of enrichment by PRISMA and physico-chemical 
properties of PRISMA peptides. Related to Figures 1 and 2. A. Distribution of the copy 
number. Estimations based on the iBaq quantification for the PRISMA screen and the 
nuclear extracts. Both, nuclear extracts and PRISMA binders are in the same copy number 
range. B. Correlation of the accumulated intensity of the PRISMA binders to different 
peptide properties. C. Binding of proteins in the PRISMA screen in comparison to various 
calculated peptide properties. The top panel shows the accumulated binding intensity of the 
PRISMA binders, while the other panels show the different calculated peptide properties for 
the peptides listed below. 
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Supplemental Figure 2: Internal C/EBPβ connections and GO term distribution. 
Related to Figure 2. A. Co-binding of interaction partners to different C/EBPβ regions. The 
number of interaction partners was calculated that bind to two different regions, as indicated 
on the abscissa. Dot sizes represent the number of binding partners in the C/EBPβ regions, 
while the width of the arcs represent the number of interaction partners found in the 
connected regions. B. Enrichment analysis of GO-terms for binding partners in the different 
regions of C/EBPβ. GO-terms were selected for DNA related processes (pink), nuclear 
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Supplemental Figure 3: Potential C/EBPβ interacting protein complexes. Related to 
Figure 3. Complex coverage and p-values for each of the 1432 complexes as used for the 
ranking of CORUM complexes (Additional Information below). Each dot corresponds to 
one complex. Red symbols show complexes which have less than three protein hits in 
PRISMA and SU-DHL1 data sets. Circles represent complexes ranking within the upper 
quartile (dark grey) (104 complexes, dashed line between upper quartile and lower ranks), 
triangles encode lower ranking complexes. The 104 highest ranking complexes are shown in 
the close-up on the right. Highest ranking complexes for each of the 14 categories from Fig. 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CR2 CR3 CR4 CR5 CR6CR1 CR7 BA DB Fork LZ CP
TAD RD bZIP
MHRLLAWDAACLPPPPAAFRPMEVANFYYEPDCLAYGAKAARAAPRAPAAEPAIGEHERAIDFSPYLEPLAPAAADFAAPAPAHHDFLSDLFADDYGAKPSKKPSDYGYVSLGRAGAKAAPPACFPPPPPAALKAEPGFEPADCKRADDAPAMAAGFPFALRAYLGYQATPSGSSGSLSTSSSSSPPGTPSPADAKAAPAACFAGPPAAPAKAKAKKAVDKLSDEYKMRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQLSRELSTLRNLFKQLPEPLLASAGHC
Supplemental Figure 4: PTM-dependent binding across C/EBPβ. Related to Figure 5. 
The positions of the PTM-modified peptides are shown on the schematic presentation of the 
primary C/EBPβ sequence on top. For each peptide, the relative binding to the PTM-
modified peptides was calculated in relation to the unmodified peptide. Heatmaps display 
the relative binding of the proteins on the y-axis in relation to different PTM-carrying 
peptides, indicated below the heat maps. Red indicates enhanced binding and blue shows 
reduced binding. Note that the Figure has infinite zoom function for detailed inspection of 
data. 
Transparent Methods 
Peptide matrix synthesis 
Peptides were synthesized using the automated high-throughput SPOT-synthesis method 
(Kramer and Schneider-Mergener, 1998). Briefly, Whatman 50 cellulose membranes 
(Whatman, UK) were functionalized by coupling of Fmoc-protected b-alanine in defined spots. 
Subsequently, peptides were synthesized stepwise using standard Fmoc-chemistry. After 
each coupling step before Fmoc-deprotection, peptides that failed coupling of building blocks 
were acetylated to avoid false sequences. 
Interaction screen 
The peptide matrix membrane was blocked with yeast tRNA (1 mg/ml; Invitrogen, Karlsruhe, 
Germany) in binding buffer (20 mM HEPES pH 7.9, Merck, Germany, 0.2 mM EDTA, Merck, 
Germany, 100 mM KCl Merck, Germany, 20% glycerol, Merck, Germany, 0.5 mM DTT, Merck, 
Germany) to minimize unspecific protein binding. The membrane was then incubated with 
HeLa cell nuclear extract (5 mg/ml; Calbiotech S.A, Germany) in binding buffer supplemented 
with 0.5 mM PMSF (Merck, Germany) for 30 min, then briefly washed with binding buffer. 
Peptide spots were individually excised and bound proteins converted to peptides using a two-
step digest with endopeptidase LysC (Wako, Japan) followed by sequencing-grade trypsin 
(Promega, Germany) using a robotic setup (Kanashova et al., 2015). Peptide extracts were 
purified and stored on stage tips (Rappsilber et al., 2007). Two replicates were measured for 
each peptide spot. 
Mass spectrometry measurement for PRISMA  
Peptides were cleaned up using a stage-tip micro column (Rappsilber et al., 2007) and 
resuspended in water with 0.1% formic acid (Merck, Germany). Peptides were separated on a 
15cm reverse-phase column (packed in-house, 75 µm inner diameter, 3 µm C18-Reprosil 
beads; Dr Maisch GmbH, Ammerbruch, Germany) using a gradient to 40% acetonitrile (Merck, 
Germany) developed over 1 h 5 min. Separated peptides were ionized on a Proxeon ion source 
and directly sprayed into the online-coupled VELOS-OrbiTRAP mass spectrometer (Thermo 
scientific). MS1 spectra were recorded with a mass resolution of 60,000 in the orbitrap part of 
the machine. MS2 spectra were recorded in the VELOS. The ten most intense ions with a 
charge state greater than 1 were selected (target value = 500; monoisotopic precursor 
selection enabled) and fragmented in the linear quadrupole trap using CID (collision induced 
dissociation, 35% normalized collision energy). Dynamic exclusion for selected precursor ions 
was 60 s. Recorded spectra were analyzed using MaxQuant software package version 1.2.2.5 
(Cox and Mann, 2008) and the human IPI database (version 3.3.72), allowing for 2 missed 
cleavages. Fixed modifications were set to cysteine carbamylation, and variable modifications 
were set to methionine oxidation, as well as N-terminal protein acetylation. Each replicate was 
analyzed separately with the label-free option activated for data quantification (Cox et al., 
2011).  
Analysis of nuclear cell extracts 
Nuclear cell extracts were supplemented with the USP2 standard (Merck, Germany) and 
digested as described above on an automated digestion setup (Kanashova et al., 2015). 
Peptides were fractionated by RP-HPLC with Proxeon nLC2 and further analyzed by a 
QExactive mass spectrometer (Thermo Scientific). The mass spectrometer was operated in a 
data-dependent acquisition mode with dynamic exclusion enabled (30 s). MS1 (mass range 
300-1700 Th) was acquired at a resolution of 70,000 with the ten most abundant multiply 
charged (z ≥ 2), ions selected with a 2 Th isolation window for HCD (Higher-energy collisional 
dissociation) fragmentation. MS2 scans were acquired at a resolution of 17,500 and injection 
time of 60 ms. 
  
Full-length C/EBPβ interactome analysis by AP-MS mass spectrometry 
Eluates from control immunoglobulins (IgG) and anti-C/EBPβ pull-downs (four replicates each) 
were ethanol precipitated and protein pellets were solubilised in urea buffer (6 M urea, 2 M 
thiourea, 20 mM HEPES pH 8), reduced for 30 min at RT in 10 mM DTT, followed by alkylation 
with 55 mM chloroacetamide (Merck, Germany) for 20 min in the dark at RT. The 
endopeptidase LysC (Wako, Japan) was added at a protein:enzyme ratio of 50:1 and 
incubated for 4h at RT. After dilution of the sample with 4´ digestion buffer (50 mM ammonium 
bicarbonate pH 8), sequence-grade modified trypsin (Promega, Darmstadt, Germany) was 
added (protein:enzyme ratio = 100:1) and digested overnight. Trypsin and LysC activity was 
quenched by acidification with trifluoroacetic acid (TFA) added to pH ~2. Afterwards, peptides 
were extracted and desalted using the standard StageTip protocol (Rappsilber et al, 2003). 
Peptide mixtures were separated by reverse-phase chromatography using an Eksigent 
NanoLC 400 system (Sciex, Darmstadt, Germany) on in-house-manufactured 20 cm fritless 
silica microcolumns with an inner diameter of 75 µm. Columns were packed with ReproSil-Pur 
C18-AQ 3 µm resin (Dr Maisch GmbH). Peptides were separated using an 8-60% acetonitrile 
gradient (ran over 224 min) at a nanoflow rate of 250 nl/min. Eluting peptides were directly 
ionised by electrospray ionization and analyzed on a Thermo Orbitrap Fusion instrument (Q-
OT-qIT, Thermo). Survey scans of peptide precursors from 300 to 1500 m/z were performed 
at 120 K resolution with a 2×105 ion count target. Tandem MS was performed by isolation at 
1.6 m/z with the quadrupole, HCD fragmentation with a normalized collision energy of 30, and 
rapid scan MS analysis in the ion trap. The MS2 ion count target was set to 2×103 and the max 
injection time was 300 ms. Only precursors with a charge state of 2–7 were sampled for MS2. 
The dynamic exclusion duration was set to 60 s with a 10 ppm tolerance around the selected 
precursor and its isotopes. The instrument was run in top speed mode with 3 s cycles, meaning 
the instrument could continuously perform MS2 events until the list of non-excluded precursors 
diminished to zero or 3 s. Data were analyzed by MaxQuant software version 1.5.1.2. The 
internal Andromeda search engine was used to search MS2 spectra against a decoy human 
UniProt database (HUMAN.2014-10) containing forward and reverse sequences. The search 
included variable modifications of methionine oxidation and N-terminal acetylation, 
deamidation (N and Q) and fixed modification of carbamidomethyl cysteine. The minimal 
peptide length was set to seven amino acids, and a maximum of two missed cleavages were 
allowed. The FDR was set to 0.01 for peptide and protein identifications. Unique and razor 
peptides with a minimum ratio count of 1 were considered for quantification. Retention times 
were recalibrated based on the built-in nonlinear time-rescaling algorithm. MS2 identifications 
were transferred between runs with the ‘Match between runs’ option, in which the maximal 
retention time window was set to 0.7 min. Statistical analysis was performed using Perseus 
version 1.5.2.4. C/EBPβ pull-down and control samples were defined as groups and proteins 
and filtered by intensity value using a ‘minimum value of 3 per group’ as the threshold. After 
log2 transformation, missing values were imputed with random numbers from a normal 
distribution with a mean and standard deviation chosen to best simulate low abundance values 
below the noise level (width = 0.3; shift = 1.8). Significantly enriched proteins were determined 
using a volcano plot-based strategy, combining standard two-sample t-test p-values with ratio 
information. Significance corresponding to an FDR of 5% was determined by a permutation-
based method (Tusher et al., 2001). Equal sample load was confirmed by calculating the ratio 
of antibody intensities (mean log2 ratio = 0.1575). 
Identification of C/EBPβ PTM sites by mass spectrometry 
Eluates of anti-C/EBPβ pull-downs were ethanol precipitated and protein pellets were 
processed as described above for the interactome analyses. Peptides were analyzed on a 
Thermo Orbitrap Fusion instrument (Q-OT-qIT, Thermo). Sequential survey scans of peptide 
precursors covering different mass ranges (300-600, 550-850, 800-1100, 1050-1700 m/z) 
were performed at 120 K resolution with a 2×105 ion count target on the three most abundant 
precursor ions. Tandem MS was performed by isolation at 1.6 m/z with the quadrupole, HCD 
fragmentation with a normalized collision energy of 30, and rapid scan MS analysis in the ion 
trap. The MS2 ion count target was set to 1×104 and the max injection time was 500 ms. Only 
precursors with a charge state of 2–7 were sampled for MS2. The dynamic exclusion duration 
was set to 60 s with a 10 ppm tolerance around the selected precursor and its isotopes. Data 
were analyzed by MaxQuant software version 1.5.1.2 as described above for interactome 
analysis with some modifications; the search included variable modifications of methionine 
oxidation and N-terminal acetylation, deamidation (N and Q), phosphorylation (S, T and Y), 
acetylation (K), methylation (K and R), dimethylation (K and R), trimethylation (K) and 
citrullination (R). Modification of carbamidomethyl cysteine was set as a fixed modification. The 
minimal peptide length was set to seven amino acids, and a maximum of four missed 
cleavages were allowed. The FDR was set to 0.01 for site identifications. To filter for confidently 
identified peptides, the MaxQuant score was set to a minimum of 40. Identified PTM sites were 
classified according to their localization probability (Class I >0.75, Class II >0.5, Class 3 >0.25). 
In order to distinguish citrullination from deamidation, a modification resulting in a similar mass 
shift of the precursor, both modifications were included during MaxQuant data analyses as 
variable modifications, and at least one missed cleavage was required for citrullination site 
identification. When arginine and lysine are acetylated or methylated, trypsin often fails to 
cleave at that site, resulting in miss-cleaved peptides. Therefore, only the PTM sites, which 
were identified within the peptide, but not C-terminally localized, were considered as 
confidently identified. 
Combining the two datasets and data filtering 
The two datasets of the PRISMA measurement were analyzed in two batches due to 
restrictions of the MaxQuant software package. The two separate datasets were then 
integrated by calculating the average intensity value where two values were available, or by 
taking the single measured value if only one intensity measurement was available to prevent 
bias against single identifications. Single value intensities were annotated as lower confidence 
quantifications. Each of the data rows of the combined dataset, corresponding to intensity 
values of one protein over all 203 peptides, was first filtered according to the outlier criterion 𝐼" = 0	𝑖𝑓	𝐼" ≤ 𝑃90, where In is the intensity at peptide n, and P90 is the 90th percentile of the 
intensity value distribution of the protein, followed by normalization against the intensity of the 
highest value in each row using +,-./0 ( +0) = 	 𝐼", where In is the intensity at peptide n. This was 
followed by an additional filtering step where all proteins were removed that did not show a 
consecutive binding pattern according to finding at least one intensity In with In > 0 and In+1 > 0 
with In as the intensity at peptide n and only considering peptides without any PTM. 
Construction of CORUM networks 
For each complex identified in the CORUM database, the corresponding UniProt identifier was 
extracted and translated to an ensemblp identifier using the bioDBnet conversion tool 
(Mudunuri et al., 2009). For each of the ensemblp identifiers, interactions were extracted from 
the STRING resource (Szklarczyk et al., 2015). The interaction network was constructed using 
the igraph software package (Csardi G, 2006) and colored based on the source the of the 
interaction from the different datasets. 
Relative binding to PTM-modified peptides 
For each peptide and its PTM derivatives, the relative binding was calculated. For each protein 
and modified peptide, the intensity value of the unmodified form of the peptide was subtracted. 
The resulting values were separated into five fractions and clustered according to their 
Euclidian distance.  
Calculation of peptide properties 
For calculation of peptide properties, the R peptides package was used, and properties were 
calculated and plotted using the ggplot2 packages (Wickham, 2009). 
 
Use of the DAVID package 
A total of 1375 identifiers were examined using the Generic Gene Ontology Term Finder 
(GGOTF, Princeton University, Lewis-Sigler Institute for Integrative Genomics) to assess 
ontology aspects, functions, and components. 
Immunoprecipitation of endogenous C/EBPβ for mass spectrometry 
Immunoprecipitation of C/EBPβ from 4´108 SU-DHL1 cells (anaplastic large cell lymphoma, 
DSMZ, ACC 356) was performed after washing twice with phosphate-buffered saline (PBS) 
and resuspension in lysis buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA pH 8), 1 µM ZnCl2 (Merck, Germany), 0.1% NP40 (Sigma, Germany), 2 mM dithiothreitol 
(DTT), 2 mM PEFAbloc (Böhringer, Mannheim, Germany) supplemented with protease 
inhibitor cocktail (Roche, Germany), and 20 U/ml benzonase (Sigma, Germany). After 
incubation on ice for 10 min, lysates were sonicated twice for 1 min, cell debris was removed 
by centrifugation at 70,000 g for 30 min, and lysates were filtered through a 0.45 µM filter 
(Whatman, Maidstone, UK) prior to immunoprecipitation. Samples were immunoprecipitated 
with a C/EBPβ antibody mix for 30 min at 4°C (Santa Cruz; C-19 and a customized polyclonal 
antibody raised against the human recombinant C/EBPβ protein) and immunoprecipitates 
were subsequently collected on Protein-G Dynabeads (Novex, Life Technologies). Beads were 
washed twice in lysis buffer without benzonase, once in lysis buffer without benzonase and 
NP40, and eluted by incubation with a mix of 6 M urea and 2 M thiourea (Sigma) for 15 min at 
25°C. Immunoprecipitation specificities were controlled by immunoprecipitation of SU-DHL1 
lysates with nonspecific rabbit IgG control antibodies (Santa Cruz, sc-2017) and subsequent 
collection on Protein-G Dynabeads. 
Cell culture, transfection, immunoprecipitation and immunoblotting 
HEKT-293 cells were grown in Dulbecco’s modified Eagle medium (DMEM; Invitrogen, USA) 
and SU-DHL1 cells were grown in RPMI (Invitrogen, USA) supplemented with 10% FCS and 
1% penicillin/streptomycin (Invitrogen, USA). Transfection of plasmids in HEKT-293 cells was 
performed by calcium-phosphate precipitation or Metafectene (Biontex, Munich, Germany) 
according to the manufacturer’s protocol. For validation of PRISMA-identified C/EBPβ protein 
interactions, immunoprecipitation of WT or mutant C/EBPβ proteins expressed in HEKT-293 
cells was performed as described previously (Kowenz-Leutz et al, 2010). Briefly, cell lysates 
were prepared in lysis buffer and immunoprecipitation was performed with appropriate 
antibodies for 2 h at 4°C. Immunoprecipitated proteins were collected on Protein-G Dynabeads 
(Novex), separated by SDS-PAGE (NuPAGE, Thermo-Fisher, Waltham, USA) and 
immunoblots were incubated with appropriate antibodies as indicated and visualized by ECL 
(GE Healthcare, UK). GST-C/EBPβ constructs and cloning of mutant C/EBPβ proteins were 
as described previously (Kowenz-Leutz et al 1999; 2010 etc). Antibodies were as follows: anti-
C/EBPβ (Leutz lab), anti-C/EBPβ (Santa Cruz; C-19), anti-Flag (Sigma), anti-HA.11 
(Covance), anti-TLE3 (Santa Cruz; sc-9124), anti-WDR77/Mep50 (Biomol; A301-562A), anti-
Nup50 (Santa Cruz; sc-133859), anti-Mi2 (Santa Cruz; sc-11378; Santa Cruz; sc-11378), anti-
MBD2 (Santa Cruz; sc-12444), anti-MBD3 (Bethyl; A302-538A), anti-PRMT5 (Millipore; 07-
405), anti-MTA1 (Biomol; A200-280A), DMAP1 (Santa Cruz; B-10), anti-RbbP4 (Abcam), Stat3 
(Cell signaling; 9132P), anti-RelA (Santa Cruz; sc-109, anti-GCN5 (H-75; Santa Cruz; SC-
20698), anti-ELL (Bethyl; A301-644A), anti-cyclin T1 (Bethyl; A303-499A-M), anti-CDK9 
(Bethyl; A303-493A-M), anti-AF9 (Novus; NB100-1565), anti-MLLT1 (Novus; NBP1-26653), 
anti-PAF1 (Novus; (NB600-274), anti-BRD4 (Bethyl; A301-985A50), anti-AF4 (Santa Cruz; sc-
99062), anti-GFP (Roche; 11814460001), anti-SSRP1 (Thermo; PA-22186), anti-SPT16 
(Thermo; PA1-12697). 
  
In vitro methylation assay 
Peptides, #1-7 (PSL, Heidelberg, Germany) used for in vitro methylation were based on the 
mouse C/EBPβ homolog. Peptide sequences are: 
#1: MHRLLAWDAASLPPPPAAFRP,  
#2: MEVANFYYEPDSLAYGAKAARAAPRAAPAAEPAIG, 




#7: MAAGFPFALRAYLGYQATPSGSSGSLSTSSSSSPPGTPSPDADKA.  
Methylation assays were carried out with PRMT4/CARM1 (#51047, BPS Bioscience) in the 
presence of S-adenosyl-L-(methyl)-3H methionine as methyl donor and incorporation of (3H)-
methyl was determined by scintillation counting (Kowenz-Leutz et al 2010).  
Adipogenesis and RT-PCR analysis  
Adipogenic differentiation of was performed with C/EBPβ WT, R193A,L mutant and TLE3 
constructs were transfected into 3T3L1 fibroblasts and cells were grown in the absence of the 
adipogenic differentiation cocktail (IBMX, Insulin, Dexamethasone) (Kowenz-Leutz et al 2010). 
Total RNA was isolated (#R1055, Zymo) and cDNA was prepared (#K1622, ThermoScientific). 
Real-time PCR was performed using SYBR Green (#A25741, Applied Biosystems and the 
Quant Studio 6 Flex Cycler (Applied Biosystems). Primers were used as described (Villanueva 
et al., 2013). Primer sequences: m36B4 forward AGATGCAGCAGATCCGCAT and reverse 
GTTCTTGCCCATCAGCACC; ADIPOQ forward CCGGAACCCCTGGCAG and reverse 
CTGAACGCTGAGCGATACACA; CFD forward CATGCTCGGCCCTACATGG and reverse 
CACAGAGTCGTCATCCGTCAC; FABP4 forward CACCGCAGACGACAGGAAG and reverse 
GCACCTGCACCAGGGC. 
Adipogenic cell differentiation was visualized after fixation with 4% paraformaldehyde by oil 
red O staining.  
Homolog mapping and calculation of overlap with known datasets 
The two Siersbaek interaction datasets (Siersbaek et al., 2011) are based on the mouse 
homolog of C/EBPβ and thus all identifiers were mapped to human homologs prior to 
calculating the overlap between the datasets using the InParanoid Homolog database 
(http://inparanoid.sbc.su.se/cgi-bin/index.cgi). PRISMA data was organized into protein groups 
reflecting the non-unique mapping of peptides to the protein sequences. Within PRISMA data, 
the unique IPI identifiers served for overlap calculation. Otherwise, the overlap of a set of 
protein groups (reference dataset) with another dataset was calculated by determining all 
mutual UniProt identifiers in the two datasets and projecting them onto the protein groups of 
the reference dataset.  
Calculations of dataset overlaps 
Overlap of proteins in the full PRISMA dataset (replicates 1 and 2), the PRISMA core 
interaction set, and the three other datasets (MudPIT HeLa, IP 3T3L1, and IP SU-DHL1) and 
their union is shown in the following table. Entries in the diagonal capture the total number of 




















2363 1302 57 483 1014 1179 
PRISMA core 
interactions 
1302 1302 35 390 716 829 
MudPIT HeLa 69 46 118 23 43 118 
IP 3T3L1 447 372 23 630 349 630 




1078 807 118 630 1369 1721 
FDR calculation 
To estimate the false discovery rate (FDR) of protein-protein interaction (PPI) data sets, we 
employed the method proposed by D’haeseleer and Church (2004) which relies on comparing 
the intersections of two measured datasets with a reference set to approximate the number of 
false-positive PPIs in the measured datasets (see figure below). We thereby assumed that 
the reference set and the intersection between the two measured datasets is error-free (i.e. 
they contain no false-positives).   
Scheme S1: Scheme for the calculation of the false discovery rate (FDR) of dataset 1 
according to D’haeseleer & Church (2004). It is assumed that the intersections of the 
reference set with the datasets (I, III) as well as the intersection between the two datasets (II) 
are nearly error-free. In addition, the method makes use of the assumption that the reference 
set overlaps similarly with dataset 1 and dataset 2 (i.e. the relation IV / III = II / I holds. |dataset 
1| denotes the number of proteins in dataset 1.  
The assumption that the reference set is error-free can be relaxed since we only need to be 
sure that it contains no bias in how it intersects with the first and second measured datasets 
and their intersection [D’haeseleer and Church, 2004]. This can be expected if both measured 
datasets are obtained using the same measurement method, which is the case for PRISMA 
SET1 and SET2.  
Using the calculation procedure described in the figure above for PRISMA SET1 and SET2 
with the union of the IP SU-DHL1, IP 3TL3L1 and MudPIT HeLa datasets as reference set, we 
estimated FDRs of 11.2% and 13.9% for SET1 and SET2, respectively. If using as the two 
measured datasets the restrictions of SET1 and SET2 to proteins also occurring in the 
PRISMA core interaction set, the FDRs were reduced to 2.5% (SET1∩PRISMA core 
interactions) and 3.3% (SET2∩PRISMA core interactions). Overlap counts of the PRISMA sets 
and the reference set (union of IP SU-DHL1, IP 3TL3L1, MudPIT HeLa) which are needed for 
FDR calculation (i.e. values for the sizes of areas marked by I, II, III, IV, V in the figure above) 
are given in the following table. 
Set size I II III IV V FDR 
SET1 1896 862 522 186 113 213 11.2% 
SET2 1851 862 522 131 79 257 13.9% 
SET1∩PRISMA core 
interactions 
1203 738 359 51 25 30 2.5% 
SET1∩PRISMA core 
interactions 
1196 738 359 40 19 40 3.3% 
Ranking of CORUM complexes 
We ranked the 1432 complexes obtained from the CORUM database as described in the main 
text by applying a combination of two criteria: (i) the percentage of proteins of the complex 
occurring in PRISMA, and (ii) deviation from randomness of the coverage obtained for PRISMA 
and SU-DHL1. Specifically, for (i), we calculated the percentage for each complex by dividing 
the number of proteins occurring in the complex from the combined PRISMA replicates 1 and 
2 (SET1 + SET2) with matched identifiers using the Perseus tool by the total number of 
proteins in the complex. For (ii), for each complex, we compared the PRISMA (SU-DHL1) 
dataset with random protein sets in terms of how many proteins of the complex are covered. 
Focusing on CORUM data, we considered only the subset of PRISMA and SU-DHL proteins 
which occurred in the 2678 proteins from the 1432 CORUM complexes, comprising 816 (490) 
proteins in the PRISMA (SU-DHL) dataset, thus also giving the size of the corresponding 
random datasets. We first performed the calculations separately for PRISMA and SU-DHL for 
each of the 1432 complexes. For calculation of a complex of Cn >1 proteins, of which Cp 
proteins with 0 £Cp £Cn occur in PRISMA, we estimated the probability of observing at least 
Cp of Cn specific proteins within a random set of size Pn = 816 drawn from the total set of 
Tn = 2678 proteins occurring in any of the CORUM complexes. This is a ‘drawing without 
replacement’ scenario (corresponding to the Fisher’s exact test), for which success is 
represented by drawing one of a specific subset (of size Cn) of proteins, and thus the 
probability that at least X successes are obtained can be calculated as follows: 
	𝑃(𝑋 ≥ 𝐶𝑝) =7 89"9 :	8;"<9"="<9 :8;"=":9"9>9?  
where Cn is the maximal number of successes (full coverage of a complex of size Cn), C is 
the number of successes (a minimum of C = Cp proteins of the complex covered because this 
is how PRISMA or SU-DHL performed, and a maximum of C=Cn), Tn = 2678 (the number of 
possible results for drawing, which is the number of different proteins in the 1432 CORUM 
complexes), and Pn (the number of draws or size of the random datasets) = 816 (for PRISMA 
full) and 490 (for SU-DHL1). 
For calculation of the probabilities for different complexes, the values of Cn and Cp, but not of 
Tn and Pn, can change. The probabilities correspond to a hypergeometric distribution, and we 
employed the appropriate R base function (dhyper) to compute the values. 
The obtained probabilities for each complex, one for PRISMA and one for SU-DHL1, represent 
how probable it is to obtain the observed (or a more extreme) coverage by chance. We treated 
the events for PRISMA and SU-DHL1 as independent and multiplied the two probabilities for 
each complex to obtain the probability that both coverages (or a more extreme) occurred by 
chance.  
We ranked the 1432 complexes based on criterion (i) and (ii) separately. For (i), a high rank 
corresponded to a high percentage; for (ii), a high rank corresponded to a high significance 
(i.e. to a low probability; function rank in R, average values for ties). We computed the final 
ranking from the sum of the two previous rankings (applying minimal values for ties). The 
complex list is shown together with the probabilities and rankings in Supplemental Table 5. 
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